妊娠前接种四价人乳头瘤病毒疫苗与妊娠结局的全国性病例对照研究
该研究基于瑞典2006至2023年全国单胎初产妇女数据,采用匹配病例对照设计,评估孕前接种四价HPV疫苗与不良妊娠结局的关联。调整混杂因素后,接种与早产、自发早产、极早产、早产前胎膜早破及严重小于胎龄儿风险降低相关,且年轻时接种者风险降低更明显。
要点
- 孕前接种四价HPV疫苗与早产风险降低相关(aOR 0.95,95%CI 0.91-0.99)。
- 接种与极早产、自发早产、早产前胎膜早破及严重小于胎龄儿风险降低相关。
- 年轻时接种者风险降低更明显,提示HPV疫苗获益超越癌症预防。
核心结论
- 孕前接种四价HPV疫苗与不良妊娠结局风险降低相关,尤其年轻接种者更明显。
主要发现
- 调整混杂后,早产(<37周)aOR 0.95(95%CI 0.91-0.99),极早产(28-31周)aOR 0.85(0.75-0.97),自发早产aOR 0.95(0.91-0.99),早产前胎膜早破aOR 0.93(0.87-1.00),严重小于胎龄儿aOR 0.92(0.87-0.97)。
- 所有纳入的不良妊娠结局均显示接种后比值降低,年轻接种者风险降低更明显。
关键数值与推荐
- 主要结局为早产(<37周)及其亚型、自发早产;次要结局包括早产前胎膜早破、胎膜早破、小于胎龄儿(<第10百分位)、严重小于胎龄儿(<第3百分位)、死产及新生儿死亡。
临床怎么用
- 全科医生可向育龄女性说明孕前接种四价HPV疫苗与不良妊娠结局风险降低相关,鼓励适龄接种。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between quadrivalent human papillomavirus vaccination before pregnancy and subsequent risk of adverse pregnancy outcomes. DESIGN: Nationwide, population based matched case-control study. SETTING: Population of Sweden, from 1 January 2006 to 31 December 2023. PARTICIPANTS: 624 713 singleton births among nulliparous women aged 16-35 years in Sweden between 2006 and 2023; 92 620 (14.8%) women had received quadrivalent human papillomavirus vaccination before pregnancy. MAIN OUTCOME MEASURES: Risk of adverse pregnancy outcomes associated with quadrivalent human papillomavirus vaccination, with preterm birth (<37 weeks), including its subtypes, and spontaneous preterm birth as primary outcomes and preterm prelabour rupture of membranes, prelabour rupture of membranes, small for gestational age infant (<10th centile), severe small for gestational age infant (<3rd centile), stillbirth, and neonatal mortality as secondary outcomes. Effect modification by age at human papillomavirus vaccination was assessed. Conditional logistic regression was used to estimate odds ratios and adjusted odds ratios with 95% confidence intervals (CIs). RESULTS: After adjustment for confounders, quadrivalent human papillomavirus vaccination was associated with lower odds of all included adverse pregnancy outcomes. Statistically significant associations were observed for preterm birth (<37 weeks) (adjusted odds ratio 0.95, 95% CI 0.91 to 0.99), very preterm birth (28 weeks to 31 weeks) (0.85, 0.75 to 0.97), spontaneous preterm birth (0.95, 0.91 to 0.99), preterm prelabour rupture of membranes (0.93, 0.87 to 1.00), and severe small for gestational age infant (0.92, 0.87 to 0.97). Risk reduction was generally more pronounced among women vaccinated at younger ages. CONCLUSIONS: Quadrivalent human papillomavirus vaccination before pregnancy was associated with a lower risk of adverse pregnancy outcomes, particularly among women vaccinated at earlier ages, extending benefits of human papillomavirus vaccination beyond cancer prevention.
引用
- Zhang Z, Ploner A, Sengpiel V, et al. Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study. BMJ. 2026. PMID: 42843853. doi:10.1136/bmj-2026-100739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。